Bortezomib liposomal (The WhiteOak Group)

硼替佐米脂质体（The WhiteOak Group）

Report date: 2022/11/17 15:45:06

Base Information

Drug NameBortezomib liposomal (The WhiteOak Group)
Drug Alias NameMyzomibWGI-0401硼替佐米改良型（The WhiteOak Group）
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProteasome inhibitors
TargetsProteasome
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesThe WhiteOak Group LLC
China Registration ClassN/A

Develop Information

Active CompaniesThe WhiteOak Group LLC
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A